Study Design: This is a level III retrospective cohort study.
S
pinal surgery is associated with the potential for significant blood loss, and the adequate control of surgical bleeding is paramount to the success of the operation. Tranexamic acid (TXA) blocks the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator, reversibly impeding the processes of fibrinolysis and clot degradation. [1] [2] [3] [4] Both TXA and epsilon aminocaproic acid (EACA) have been demonstrated in the literature to be beneficial in states where there is an excess of fibrinolysis relative to the coagulation cascade. [1] [2] [3] [4] TXA has been shown in multiple randomized controlled trials and meta-analyses to be beneficial in the reduction of perioperative blood loss and the subsequent need for blood transfusion in cardiac surgery and total joint arthroplasty. [5] [6] [7] [8] [9] [10] Enhanced fibrinolysis is also a contributing factor to blood loss in spinal surgery, but most spinal literature on perioperative TXA administration has considered operations performed for major adult and pediatric spinal deformity. Although 1 and 2-level posterior lumbar fusion operations compose a substantial percentage of annual spine surgeries performed, 11, 12 little has been specifically reported regarding the use of TXA as a means by which to reduce perioperative blood loss, mean operative time, and associated morbidity and cost during these routine operations.
To our knowledge, there is no current published study that has considered the effect of routine administration of TXA in posterior approach 1 and 2-level lumbar interbody fusion operations. The study that most closely approximates this analysis, published by Wang et al 13 in 2012, included cases of long segment fixation which significantly increase surgical exposure required and subsequent blood loss. The purpose of the present study, therefore, is to investigate whether prophylactic TXA administration before 1 and 2-level posterior lumbar interbody fusion operations reduces perioperative blood loss (including intraoperative blood loss and postoperative drain output) and mean operative time, and to determine if statistically significant reductions in rates of postoperative transfusion and postoperative thromboembolic events are noted when TXA is administered prophylactically.
MATERIALS AND METHODS

Patient Enrollment
Two groups, a study group composed of 75 patients who underwent 1 and 2-level posterior lumbar interbody fusion operations for degenerative indications who received TXA before the start of the procedure, and a control group composed of 75 patients who underwent similar surgeries for the same indications and did not receive TXA preoperatively, were retrospectively enrolled. IRB approval was obtained through the institutional review board at the University of Nebraska Medical center. All patients between November 2013 until April 2017 who underwent posterior approach lumbar spinal surgery performed by the senior author were analyzed. Patients who had revision operations, operations performed for nondegenerative indications, or those who had operations other than 1 and 2-level posterior approach lumbar interbody fusions were excluded from analysis. Because of the potential associated effect on perioperative blood loss, cases involving harvest of iliac crest bone graft were also excluded. A power analysis was performed which indicated that 75 patients were required in each group to attain the necessary power to make statistically significant assertions. The senior author begin using TXA routinely in June 2015. Patients that underwent the described operations from November 2013 to June 2015 were screened for inclusion in the "non-TXA" group, and patients that underwent similar operations from June 2015 until April 2017 were screened for inclusion in the "TXA" group. 
Operative TXA Administration
All patients in the study population underwent 1 and 2-level lumbar interbody fusion operations performed for degenerative indications at the University of Nebraska Medical Center between the November 2013 and April 2017. All surgeries were performed by the senior author (C.C.). Patients were placed in a prone position on the Jackson Spinal frame. After the operative field was prepared and draped, the first dose of 1 g intravenous TXA was administered within 15 minutes of starting the procedure. For ease of standardization and administration of the drug, weight-based dosing was not utilized as part of the senior author's protocol. A standard midline incision was made to expose the levels necessary to perform the decompression and fusion. In all cases, laminectomy, partial medial facetectomies, and bilateral foraminotomies were performed at the affected levels to decompress the neural elements, then transforaminal lumbar interbody fusion cages were inserted in standard manner via gentle retraction of the dura to the side. Transverse processes were decorticated, and posterior instrumented fusion was performed via placement of pedicle screws that were connected with rods. Bone grafting of the posterolateral gutters was then performed using either local bone graft or allograft. At the completion of the procedure while a layered closure was being performed, a second dose of 1000 mg IV TXA was administered. Jackson Pratt drains were placed for all patients postoperatively, and drain outputs were recorded by nursing staff based on amount of drainage present in the JP bulb in 8-hour intervals until their removal the day of discharge or at the time of the first dressing change.
Retrospective Data Collection
After exclusion was complete, 75 patients in the TXA group and 75 patients in the non-TXA group remained. Demographic data was then collected including age, sex, body mass index, history of bleeding disorders, and surgery type (1 or 2-level posterior lumbar interbody fusion). Laboratory data was collected including preoperative hemoglobin, hematocrit, and platelets. Preoperative laboratory blood count data was readily available as part of the standard preoperative evaluation, and was included in the analysis. Similar postoperative laboratory data was incompletely available in the medical record, and was thus excluded from analysis. Surgical data was collected including estimated intraoperative blood loss, postoperative day 1 to 3 drain output, total drain output, mean surgical time, postoperative venous thromboembolic events, and postoperative transfusion rates (postoperative transfusion vs. no postoperative transfusion). Descriptive statistics (means, SD, medians, counts, and percentages) were used to summarize demographic and clinical characteristics between the groups. Fisher exact test was used to analyze associations of categorical variables with TXA status. The Mann-Whitney test was used to compare continuous measurements between the TXA groups. All analyses were done using SAS, Version 9.4. P < 0.05 was considered statistically significant.
RESULTS
No statistically significant differences were noted between any of the demographic data between TXA and non-TXA groups, including age (P = 1.0), sex (P = 1.0), and body mass index (P = 0.59). No statistically significant differences were noted between surgery type (1 vs. 2-level posterior interbody fusion) (P = 0.74), use of home anticoagulation (P = 0.39), administration of postoperative anticoagulation (P = 1.0), presence of bleeding disorder (P = 1.0), postoperative venous thromboembolic events (P = 1.0). No statistically significant differences were noted with regards to preoperative hemboglobin (P = 0.38) and hematocrit (P = 0.17), estimated intraoperative blood loss (P = 0.21), postoperative day 2 drain output (P = 0.39), or postoperative day 3 drain output (P = 0.78). No postoperative transfusions were required in either group (P = 1.0). Conversely, statistically significant differences were noted between the groups with regards to postoperative day 1 drain output (P < 0.0041), total postoperative drain output (P = 0.027), and mean surgical time (P < 0.0001), with reductions noted in the TXA group with respect to the non-TXA group across all statistically significant parameters. A reduction in mean operative time of 42 minutes was noted between non-TXA and TXA groups, with average operative time in the non-TXA group of 194 minutes, and in the TXA group of 152 minutes. Mean postoperative day 1 drain output in the non-TXA and TXA groups were 310 and 244 mL, respectively. Mean total postoperative drain output in the non-TXA and TXA groups were 543 and 444 mL, respectively. All results are summarized in Tables 1-2 
DISCUSSION
Fibrinolysis, plasmin-mediated dissolution of fibrin clots, is the fourth stage of hemostasis. [2] [3] [4] 14 Tranexamic acid is a systemic antifibrinolytic drug that was first marketed in the 1970s. It is similar to the prototypical synthetic antifibrinolytic, EACA, but ∼10 times more potent. It blocks the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator, reversibly impeding fibrinolysis and clot degradation. In a recent study by Pong and colleagues, in patient undergoing adult spinal deformity surgery, intravenous administration of tranexamic acid was found to be effective at reducing intraoperative blood loss. [14] [15] [16] Further, the study found that monitoring of D-dimer and fibrinogen during spinal surgery suggested that tranexamic acid impedes the fibrinolytic pathway by decreasing consumption of fibrinogen and clot dissolution as evidenced by the reduced formation of D-dimer. 14, [17] [18] [19] Both TXA and EACA have been demonstrated in the literature to be beneficial in states where there is an excess of fibrinolysis relative to the coagulation cascade. 13, 20 Spinal surgery is associated with the potential for significant blood loss, a finding that is intensified by a transient increase in fibrinolysis in the perioperative period. 4, [21] [22] [23] [24] Adequate control of surgical bleeding is paramount to the success of the operation. In theory, with good control of spinal surgical bleeding, visualization of the surgical field is improved, enhancing the ease of exposure and allowing for reduction in operative time required to complete the procedure.
TXA has been shown in multiple randomized controlled trials and meta-analyses to be beneficial in the reduction of perioperative blood loss and the subsequent need for blood transfusion in cardiac surgery and total joint arthroplasty. 1, 5, 6, 10 In cardiac surgery, a state of increased fibrinolysis is generated by use of a cardiopulmonary bypass machine during the operation. 10 Hardy and Desroches 10 demonstrated that TXA combats states of increased fibrinolysis, theoretically reducing blood loss in surgeries that are associated with such states. Klenerman and colleagues and Petaja and colleagues implicated intraoperative use of a tourniquet as a potential culprit in generation of profibrinolytic states in total knee arthroplasty. 5, 6 Enhanced fibrinolysis has also been implicated as a contributing factor to blood loss in spinal surgery, but its role in routine spinal surgeries such as those considered by the present study remains poorly described. Most spinal literature on perioperative TXA administration has considered operations performed for major adult and pediatric spinal deformity correction. Although posterior lumbar fusion operations compose a substantial percentage of annual spine surgeries performed, little has been reported regarding the use of TXA as a means by which to reduce perioperative blood loss, mean operative time, and associated morbidity and cost. Wang et al, 13 a notable exception, considered such operations, and demonstrated that preoperative single-dose TXA can significantly reduce postoperative blood loss in posterior approach lumbar surgery, with no significant increase in side effects in their study group. This study found significant differences in postoperative blood loss and total blood loss, but did not demonstrate a significant difference in operative time and set broad degenerative lumbar inclusion criteria for procedures included in their analysis. 13 Their analysis, however, also included cases of long segment fixation, which significantly increase surgical exposure required and subsequent blood loss. 13 A further association between routine prophylactic perioperative TXA administration and reduced mean operative time and postoperative drain output, with a focus on routine 1 and 2-level posterior lumbar interbody fusion operations, could support TXA's routine use in these operations as a means to reduce mean operative time, reduce surgical morbidity, and contain cost. The present study considers the effects of routine TXA administration in 1 and 2-level posterior lumbar interbody fusion operations. To our knowledge, it is the first study of its kind that has considers the prophylactic use of the drug before these specific routine operations. In our study group, TXA administration before these procedures was associated with reductions in mean surgical time, postoperative day 1 drain output, and total postoperative drain output. There was no statistically significant difference between the TXA and non-TXA groups noted in postoperative venous 26 found this value to be between $36 and $37. Many institutional, contractual, and regional factors are sure affect this dollar amount, but regardless of these factors time in the operating room is expensive, and we believe the mean reduction of 42 minutes demonstrated by our study could be both clinically and economically significant. A single 1-g dose costs $8.67 at our institution, a negligible sum when compared with the potential cost savings that could be achieved via a reduction in time spent in the operating room. In addition, the risk of numerous complications including urinary tract infections, sepsis/septic shock, prolonged intubation, pneumonia, deep venous thrombosis, deep incisional infection, and wound disruption is increased with prolonged surgical time, the risk of which is diminished when time in the operating room is limited. 21 Furthermore, our study demonstrated reductions in postoperative day 1 drain output and total postoperative drain output. Mean postoperative day 1 drain output in the non-TXA and TXA groups were 310 and 244 mL, respectively. Mean total postoperative drain output in the non-TXA and TXA groups were 543 and 444 mL, respectively. Although current reports in the literature are conflicting, evidence exists linking prolonged postoperative drain utilization and duration and increased risk for surgical site infection. 27 Reduction of postoperative drain output can allow for drain removal sooner after surgery, theoretically reducing these risks and increasing potential for discharge from the hospital in a more expedient manner, thereby reducing risk of infection and other in-hospital complications and reducing the total cost of the hospitalization. There was no significant difference between the groups in estimated intraoperative blood loss (P = 0.21). This was most likely due to the inexact nature of this value. Although this value is calculated as nearly as is possible by using blood in the suction canister subtracting known volume of irrigation used, as well as blood on the drapes, lap sponges, and floor, it remains an estimate that is discussed and agreed upon by the surgeon and anesthesiologist, and not an exact measure of the intraoperative blood loss from the surgical field. The present study is not without limitations. First, this is a level III retrospective cohort study. As such, patient data was collected via retrospective chart review and patient randomization to the TXA and non-TXA groups was not possible. However, demographic data including surgery type (1 or 2-level lumbar fusions) were collected and compared between groups, and found to be comparable without any statistically significant differences between the groups. In addition, part of the mean operative time difference noted between the TXA and non-TXA groups could have been accounted for by the senior author's increasing comfort level with the procedures as the study period progressed. We do not believe this to be a significant factor contributing to this result, as the study period was relatively short, encompassing a period of just over 3 years. Also, at the outset of the study period, the senior author had been performing the procedures independently for ∼4 years and was facile at the beginning of the study period, reducing the likelihood of significant technical advancements during the period the operations were performed in. Finally, our study was limited by the collection practices employed at the time of recording of drain outputs by floor nursing staff, as well as the inexact nature of intraoperative blood loss measurement. Although postoperative outputs are gathered every 8 hours by nursing staff and assumed to be accurate, they are subject to error when values are recorded and transferred to the electronic medical record. As previously discussed, intraoperative blood loss was estimated based on blood present in suction canisters, as well as on the lap sponges, drapes, and floor of the operating room. Although the amount of irrigation was subtracted from the amount of blood suctioned in the cannister, this value remains an estimate and should be evaluated as such.
In the present study, perioperative TXA administration was associated with reduced postoperative drain output and surgical time, and was not associated with increases in postoperative venous thromoboembolic events. Its administration was performed at a negligible cost to our institution when compared with potential cost savings achieved through reduced operative time. Reduction in these parameters has the potential to lead to reduced cost and morbidity associated with longer operative times, and to reduce risk for wound complications associated with increased postoperative wound drainage. Further higher-level studies are required to investigate the safety and utility of TXA's routine use in 1 and 2-level posterior lumbar fusion operations performed for degenerative indications.
